Boehringer Ingelheim Fremont, Inc.
About Boehringer Ingelheim Fremont, Inc.
Boehringer Ingelheim is a leading research-driven biopharmaceutical company, creating value through innovation in areas of high unmet medical need.
One of the world’s largest manufacturers of biopharmaceuticals, Boehringer Ingelheim is an industry pioneer and has produced more than 40 commercial biopharmaceuticals. Our contract manufacturing business, Boehringer Ingelheim BioXcellence™ reliably supplies innovative therapies that transform lives, today and for generations to come and creates solutions with its partners to improve patient health through its production network spanning the globe, from Biberach, Germany to Vienna, Austria, Shanghai, China and Boehringer Ingelheim Fremont Inc., in California, United States.
A mammalian cell culture center in the San Francisco Bay Area, Boehringer Ingelheim Fremont, Inc., has more than 600 scientists and specialists committed to research, development, and manufacturing to deliver high quality medicines for patients. Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and process intensification technology manufacturing. With the complete range of services, from cell line and strain development, including high expression systems, through process development and large-scale manufacturing, to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality.
Biopharmaceuticals - Competence and Experience for Medicines of the Future Over 35 years ago, Boehringer Ingelheim started developing and producing biopharmaceuticals as one of the first companies worldwide. Biopharmaceuticals are produced by using either mammalian cell cultures or microorganisms such as bacteria or yeast.
1014 articles about Boehringer Ingelheim Fremont, Inc.
-
Veterinary Students Conclude Summer Research Experience With Capstone Presentations at 2022 National Veterinary Scholars Symposium - Boehringer Ingelheim
8/8/2022
This weekend, nearly 600 veterinary students representing three dozen veterinary schools from across the US, Canada, France, Germany and the Netherlands marked the conclusion of a special summer research experience with a presentation of their findings at the National Veterinary Scholars Symposium.
-
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
8/3/2022
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.
-
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
7/6/2022
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE and bioMérieux, a world leader in in vitro diagnostics, announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance.
-
Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance
7/6/2022
Evotec SE, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance.
-
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
6/28/2022
BiomX Inc. announces a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease.
-
Boehringer and BiomX intend to use the discovery platform to identify biomarkers for a pathogenic bacterium thought to be associated with IBD.
-
FDA Grants Boehringer Ingelheim Animal Health Conditional Approval for VETMEDIN®-CA1 (pimobendan) to Treat Canine Valvular Disease for Stage B2
6/21/2022
Boehringer Ingelheim Animal Health announced that the U.S. Food and Drug Administration Center for Veterinary Medicine has granted conditional approval of VETMEDIN®-CA1, which is indicated for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease, a form of chronic valvular heart disease in dogs.
-
The results demonstrated that Jardiance reduced the risk of hospitalization for heart failure compared to two other classes of glucose-lowering drugs in adults with type 2 diabetes.
-
Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study
6/5/2022
Two analyses of the final U.S. data from the EMPagliflozin compaRative effectIveness and SafEty real-world study show that Jardiance® was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adults with type 2 diabetes in routine care.
-
Proxygen partnered with Germany-based Merck to jointly identify and develop molecular glue degraders for clinical research.
-
Boehringer Ingelheim's latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
5/15/2022
Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B inhibitor, that was published in The New England Journal of Medicine.
-
Boehringer Ingelheim launches RenuTend™: a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses
4/21/2022
It takes years of diligent training as well as a trusting relationship between horse and rider to reach their full potential as a team.
-
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
4/5/2022
In 2021, Boehringer Ingelheim again stepped up its annual investments in R&D to a new high in its 137-year history.
-
Several employees at three biopharma firms are not having a very good week, as Zealand Pharma, Merck and Orchard Therapeutics all announced job cuts.
-
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
-
TeleVet and Boehringer Ingelheim Announce Strategic Collaboration
3/4/2022
TeleVet, Inc. and Boehringer Ingelheim Animal Health USA Inc. announced a strategic collaboration to deliver innovative technology and services that will make it easier for veterinary practices to provide the best patient care while alleviating stress on their teams.
-
Lifebit and Boehringer Ingelheim announce partnership to capture transformational value of health data
3/1/2022
The leading research-driven biopharmaceutical company Boehringer Ingelheim and precision medicine software company Lifebit Biotech, Ltd. announce partnership in which Lifebit will support Boehringer Ingelheim in building a scalable data, analytics, and infrastructure platform within its IT environment.
-
Eli Lilly’s Jardiance scores expanded heart failure approval from the FDA and will now be available to all patients with heart failure to reduce the risk of death and hospitalization.
-
Evotec Enters iPSC-based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology
1/25/2022
Evotec SE announced that the Company has entered a target and drug discovery partnership with Boehringer Ingelheim, focusing on induced pluripotent stem cell -based disease modelling for ophthalmologic disorders.
-
Award: Boehringer Ingelheim is Global Top Employer 2022
1/20/2022
The Top Employers Institute awarded Boehringer Ingelheim for the second year in succession a “Global Top Employer”, one of the world’s eleven best employers.